Akynzeo or Olanzapine for Patients Who Experience Breakthrough CINV in Patient Receiving Moderately or Highly Emetogenic Chemotherapy After First Cycle of Chemotherapy
The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic chemotherapy for patients who developed breakthrough CINV after cycle 1 based on the available data in the literature as well as the recommendations provided by established guidelines
100 Clinical Results associated with Simon-Williamson Clinic PC
0 Patents (Medical) associated with Simon-Williamson Clinic PC
100 Deals associated with Simon-Williamson Clinic PC
100 Translational Medicine associated with Simon-Williamson Clinic PC